Du Pont Merck: Return to the Starting Gate
Du Pont's acquisition of Merck's share of the company's pharmaceutical joint venture doesn't seem to put Du Pont in a position to address any of the problems the joint venture structure was supposed to solve--but obviously didn't. The acquisition may, in fact, be more of a response to Monsanto's aggressive moves in agriculture and its success with its GD Searle unit.
You may also be interested in...
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.
Market Intel: Why Telehealth, Digital Therapies Will Provide Mental Health Support Beyond COVID-19 Crisis
In this second part of a two-part series focusing on mental health tech, Medtech Insight highlights behavioral digital health companies that have attracted investors’ attention. Part one focused on transcranial magnetic stimulation.